MedTrace Logo

Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)

NCT01710267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2015-04-01

No results posted yet for this study

Summary

Rivaroxaban (RXA; brand name Xarelto®) is an oral direct factor Xa inhibitor that is applied for prophylaxis of venous thromboembolism after major orthopedic surgery. Additionally, RXA is approved by Swissmedic to be used at a therapeutic dose for primary therapy of VTE and for prophylaxis of cerebrovascular events in non-valvular atrial fibrillation.

This is an explorative laboratory study to evaluate the intra-individual variability of RXA conc. in time and to standardize assays among 9 Swiss laboratories to determine RXA conc.

Conditions

  • Healthy

Sponsors & Collaborators

  • Research Foundation, Division of Hematology, Luzerner Kantonsspital, Switzerland

    collaborator UNKNOWN

  • Bayer

    collaborator INDUSTRY

  • Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD

    lead OTHER

Principal Investigators

  • Walter A Wuillemin, MD PhD · Luzerner Kantonsspital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-03-31
Completion
2014-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01710267 on ClinicalTrials.gov